HighTower Advisors LLC Boosts Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

HighTower Advisors LLC boosted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4.4% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 45,731 shares of the biopharmaceutical company’s stock after buying an additional 1,944 shares during the period. HighTower Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $25,715,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the stock. Osaic Holdings Inc. raised its position in shares of Regeneron Pharmaceuticals by 55.2% in the 2nd quarter. Osaic Holdings Inc. now owns 17,068 shares of the biopharmaceutical company’s stock worth $9,607,000 after purchasing an additional 6,073 shares during the last quarter. Robeco Institutional Asset Management B.V. raised its holdings in Regeneron Pharmaceuticals by 153.4% in the third quarter. Robeco Institutional Asset Management B.V. now owns 120,884 shares of the biopharmaceutical company’s stock worth $67,969,000 after buying an additional 73,176 shares during the last quarter. PGGM Investments lifted its stake in shares of Regeneron Pharmaceuticals by 9.7% in the third quarter. PGGM Investments now owns 92,584 shares of the biopharmaceutical company’s stock worth $52,057,000 after buying an additional 8,187 shares in the last quarter. Rakuten Investment Management Inc. purchased a new stake in shares of Regeneron Pharmaceuticals during the third quarter valued at approximately $33,121,000. Finally, Simplify Asset Management Inc. increased its position in shares of Regeneron Pharmaceuticals by 34.0% during the second quarter. Simplify Asset Management Inc. now owns 3,697 shares of the biopharmaceutical company’s stock valued at $1,941,000 after acquiring an additional 939 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

REGN has been the topic of several recent analyst reports. UBS Group increased their target price on Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the company a “neutral” rating in a research note on Friday, November 7th. JPMorgan Chase & Co. increased their price objective on Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the company an “overweight” rating in a research report on Monday, February 2nd. Royal Bank Of Canada upped their target price on shares of Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the company a “sector perform” rating in a research note on Wednesday, October 29th. Canaccord Genuity Group lifted their price target on shares of Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the stock a “buy” rating in a research note on Thursday, December 4th. Finally, Oppenheimer restated an “outperform” rating and set a $865.00 price objective (up previously from $750.00) on shares of Regeneron Pharmaceuticals in a research report on Monday, February 2nd. Two analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $793.81.

Insider Transactions at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $778.53, for a total transaction of $77,853.00. Following the completion of the transaction, the director owned 17,803 shares in the company, valued at $13,860,169.59. This trade represents a 0.56% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, SVP Jason Pitofsky sold 2,036 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $778.52, for a total value of $1,585,066.72. Following the completion of the sale, the senior vice president directly owned 4,272 shares in the company, valued at approximately $3,325,837.44. The trade was a 32.28% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 3,636 shares of company stock valued at $2,862,920. 7.02% of the stock is currently owned by insiders.

Regeneron Pharmaceuticals Stock Down 0.2%

Shares of REGN opened at $792.16 on Thursday. The business’s 50 day moving average is $767.50 and its 200 day moving average is $670.90. The company has a current ratio of 4.13, a quick ratio of 3.39 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $821.11. The company has a market capitalization of $83.75 billion, a PE ratio of 19.06, a price-to-earnings-growth ratio of 2.13 and a beta of 0.40.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.74 by $0.70. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The business had revenue of $3.88 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same period last year, the firm posted $12.07 EPS. The company’s revenue was up 2.5% on a year-over-year basis. Research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 5th. Stockholders of record on Friday, February 20th will be given a dividend of $0.94 per share. The ex-dividend date is Friday, February 20th. This is a positive change from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 8.47%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.